Cobimetinib and vemurafenib for the treatment of melanoma

References

• Nikolaou V, Stratigos AJ. Emerging trends in the epidemiology of melanoma. Br J Dermatol. 2014;170:11–19.
   PubMed Web of Science ®Google Scholar
• Balch CM, Gershenwald JE, Soong S-J, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27:6199–6206.
   PubMed Web of Science ®Google Scholar
• Ranchon F, Boespflug A, Rioufol C, et al. New treatments for cutaneous metastatic melanoma: MAPK pathway-targeted and immune based therapies. Anticancer Agents Med Chem. 2015;15:461–467.
   PubMed Web of Science ®Google Scholar
• Baiter M, Schuler G, Hartmann A, et al. Pathogenetic implications of BRAF mutation distribution in stage IV melanoma patients. Dermatology. 2015;231:127–133.
   PubMed Web of Science ®Google Scholar
• Lee JJ, Sholl LM, Lindeman NI, et al. Targeted next-generation sequencing reveals high frequency of mutations in epigenetic regulators across treatment-naïve patient melanomas. Clin Epigenetics. 2015;7:59.
   PubMedGoogle Scholar
• Wan PTC, Garnett MJ, Roe SM, et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell. 2004;116:855–867.
   PubMed Web of Science ®Google Scholar
• Burotto M, Chiou VL, Lee J-M, et al. The MAPK pathway across different malignancies: a new perspective. Cancer. 2014;120:3446–3456.
   PubMed Web of Science ®Google Scholar
• Akinleye A, Furqan M, Mukhi N, et al. MEK and the inhibitors: from bench to bedside. J Hematol Oncol. 2013;6:27.
   PubMed Web of Science ®Google Scholar
• Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507–2516.
   PubMed Web of Science ®Google Scholar
• Hauschild A, Grob J-J, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012;380:358–365.
   PubMed Web of Science ®Google Scholar
• Johnson DB, Flaherty KT, Weber JS, et al. Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor. J Clin Oncol. 2014;32:3697–3704.
   PubMed Web of Science ®Google Scholar
• Larkin J, Ascierto PA, Dréno B, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med. 2014;371:1867–1876.
   PubMed Web of Science ®Google Scholar
• Zia Y, Chen L, Daud A. Future of combination therapy with dabrafenib and trametinib in metastatic melanoma. Expert Opin Pharmacother. 2015;16:2257–2263.
   PubMed Web of Science ®Google Scholar
• Johnson DB, Menzies AM, Zimmer L, et al. Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms. Eur J Cancer. 2015;51:2792–2799.
   PubMed Web of Science ®Google Scholar
• Nazarian R, Shi H, Wang Q, et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature. 2010;468:973–977.
   PubMed Web of Science ®Google Scholar
• Montagut C, Sharma SV, Shioda T, et al. Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res. 2008;68:4853–4861.
   PubMed Web of Science ®Google Scholar
• Johannessen CM, Boehm JS, Kim SY, et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature. 2010;468:968–972.
   PubMed Web of Science ®Google Scholar
• Holderfield M, Deuker MM, McCormick F, et al. Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond. Nat Rev Cancer. 2014;14:455–467.
   PubMed Web of Science ®Google Scholar
• Improta G, Leone I, Donia M, et al. New developments in the management of advanced melanoma - role of pembrolizumab. Onco Targets Ther. 2015;8:2535–2543.
   PubMed Web of Science ®Google Scholar
• Tchekmedyian N, Gray JE, Creelan BC, et al. Propelling immunotherapy combinations into the clinic. Oncology (Williston Park). 2015;29(12):990–1002.
   Web of Science ®Google Scholar
• Hoeflich KP, Merchant M, Orr C, et al. Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition. Cancer Res. 2012;72:210–219.
   PubMed Web of Science ®Google Scholar
• Choo EF, Belvin M, Boggs J, et al. Preclinical disposition of GDC-0973 and prospective and retrospective analysis of human dose and efficacy predictions. Drug Metab Dispos. 2012;40:919–927.
   PubMed Web of Science ®Google Scholar
• Wong H, Vernillet L, Peterson A, et al. Bridging the gap between preclinical and clinical studies using pharmacokinetic-pharmacodynamic modeling: an analysis of GDC-0973, a MEK inhibitor. Clin Cancer Res. 2012;18:3090–3099.
   PubMed Web of Science ®Google Scholar
• Ribas A, Gonzalez R, Pavlick A, et al. Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study. Lancet Oncol. 2014;15:954–965.
   PubMed Web of Science ®Google Scholar
• Rosen L, LoRusso P, Ma WW, et al. Abstract 4716: A first-in-human phase I study to evaluate the MEK1/2 inhibitor GDC-0973 administered daily in patients with advanced solid tumors. Cancer Res. 2011;71:4716–4716.
   Web of Science ®Google Scholar
• Musib L, Choo E, Deng Y, et al. Absolute bioavailability and effect of formulation change, food, or elevated pH with rabeprazole on cobimetinib absorption in healthy subjects. Mol Pharm. 2013;10:4046–4054.
   PubMed Web of Science ®Google Scholar
• Choo EF, Woolsey S, DeMent K, et al. Use of transgenic mouse models to understand the oral disposition and drug-drug interaction potential of cobimetinib, a MEK inhibitor. Drug Metab Dispos. 2015;43:864–869.
   PubMed Web of Science ®Google Scholar
• Takahashi RH, Choo EF, Ma S, et al. Absorption, metabolism, excretion, and the contribution of intestinal metabolism to the oral disposition of [14C]cobimetinib, a MEK inhibitor, in humans. Drug Metab Dispos. 2015;44:28–39.
   PubMed Web of Science ®Google Scholar
• Han K, Jin JY, Marchand M, et al. Population pharmacokinetics and dosing implications for cobimetinib in patients with solid tumors. Cancer Chemother Pharmacol. 2015;76:917–924.
   PubMed Web of Science ®Google Scholar
• Extended follow-up results of phase Ib study (BRIM7) of vemurafenib (VEM) with cobimetinib (COBI) in BRAF-mutant melanoma. 2015 ASCO Annual Meeting, Abstracts, Meeting Library. Available from: http://meetinglibrary.asco.org/content/143297-156
   Google Scholar
• ESMO @ ECC2015: Greater clinical benefit obtained in advanced BRAFV600-mutated melanoma with cobimetinib/vemurafenib over vemurafenib is consistent across mutation subtypes., ESMO. Available from: http://www.esmo.org/Conferences/Past-Conferences/European-Cancer-Congress-2015/News/Greater-Clinical-Benefit-Obtained-in-Advanced-BRAFV600-mutated-Melanoma-with-Cobimetinib-Vemurafenib-Over-Vemurafenib-Is-Consistent-Across-Mutation-Subtypes
   Google Scholar
• Quality-of-life (QOL) assessment in patients (pts) with metastatic melanoma receiving vemurafenib (V) and cobimetinib (C). 2015 ASCO Annual Meeting, Abstracts, Meeting Library. Available from: http://meetinglibrary.asco.org/content/143353-156
   Google Scholar
• Phase 2 study of cobimetinib in combination with vemurafenib in active melanoma brain metastases (coBRIM-B). 2015 ASCO Annual Meeting, Virtual Meeting, Meeting Library. Available from: http://meetinglibrary.asco.org/content/115268?media=vm
   Google Scholar
• Dooley AJ, Gupta A, Bhattacharyya M, et al. Intermittent dosing with vemurafenib in BRAF V600E-mutant melanoma: review of a case series. Ther Adv Med Oncol. 2014;6:262–266.
   PubMed Web of Science ®Google Scholar
• Kakavand H, Wilmott JS, Menzies AM, et al. PD-L1 expression and tumor-infiltrating lymphocytes define different subsets of MAPK inhibitor-treated melanoma patients. Clin Cancer Res. 2015;21:3140–3148.
   PubMed Web of Science ®Google Scholar
• Frederick DT, Piris A, Cogdill AP, et al. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res. 2013;19:1225–1231.
   PubMed Web of Science ®Google Scholar
• Ribas A, Hodi FS, Callahan M, et al. Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med. 2013;368:1365–1366.
   PubMed Web of Science ®Google Scholar
• Draganova D, Kerger J, Caspers L, et al. Severe bilateral panuveitis during melanoma treatment by Dabrafenib and Trametinib. J Ophthalmic Inflamm Infect. 2015;5:17.
   PubMed Web of Science ®Google Scholar
• Niro A, Strippoli S, Alessio G, et al. Ocular toxicity in metastatic melanoma patients treated with mitogen-activated protein kinase kinase inhibitors: a case series. Am J Ophthalmol. 2015;160:959–967.e1.
   PubMed Web of Science ®Google Scholar
• Chen FW, Tseng D, Reddy S, et al. Involution of eruptive melanocytic nevi on combination BRAF and MEK inhibitor therapy. JAMA Dermatol. 2014;150:1209–1212.
   PubMed Web of Science ®Google Scholar
• Matter-Walstra K, Braun R, Kolb C, et al. A cost-effectiveness analysis of trametinib plus dabrafenib as first-line therapy for metastatic BRAF V600-mutated melanoma in the Swiss setting. Br J Dermatol. 2015;173:1462–1470.
   PubMed Web of Science ®Google Scholar
• Dalle S, Poulalhon N, Thomas L. Vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;365:1448–1449. author reply 1450.
   PubMed Web of Science ®Google Scholar
• Perier-Muzet M, Thomas L, Poulalhon N, et al. Melanoma patients under vemurafenib: prospective follow-up of melanocytic lesions by digital dermoscopy. J Invest Dermatol. 2014;134:1351–1358.
   PubMed Web of Science ®Google Scholar